To explore the optimal treatment strategy to target metabolism in DLBCL cells, we evaluated the impact of combining metformin and L-asparaginase, two FDA-approved antimetabolic drugs, on DLBCL cell survival. The gene discussed is ASPG; the disease is diffuse large B-cell lymphoma.